Dateline City:
KENILWORTH, N.J.
Merck Provides Additional Update: FDA Extends Action Date for Additional sBLA in Ipilimumab-Refractory Advanced Melanoma
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the U.S. Food and Drug Administration (FDA) has accepted
for review a supplemental Biologics License Application (sBLA) for
KEYTRUDA (pembrolizumab), Mercks anti-PD-1 therapy. Merck
is seeking approval for KEYTRUDA, at the currently approved dose of 2
mg/kg every three weeks, for the first-line treatment of unresectable or
metastatic melanoma patients.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558orInvestors:Justin Holko, 908-740-1879An Phan, 908-255-6325
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more